Cultrex Basement Membrane Extract, Type 3, Pathclear
Try it on your cultures! Request a Sample of Cultrex BME, Type 3
Cultrex Basement Membrane Extract, Type 3, Pathclear Summary
Cultrex Basement Membrane Extract (BME), Type 3 is an extracellular matrix hydrogel that is qualified specifically for use in in vivo xenograft and tumorgraft models.Key Benefits
• Ideal for xenograft and tumorgraft models
• Designed to mimic the in vivo matrix microenvironment
• Quality controlled for performance consistency
Why Use Cultrex BME, Type 3?
Cultrex Basement Membrane Extract (BME), Type 3 is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumor. This extract provides a natural extracellular matrix hydrogel that polymerizes at 37°C to form a reconstituted basement membrane. Cultrex BME, Type 3 provides a proprietary formulation that is physiologically aligned with the in vivo solid tumor environment and is recommended for xenografts and other in vivo applications. This extracellular matrix hydrogel is designed to help cells to adapt to in vivo transplantation. It mimics the in vivo microenvironment, including low glucose and low pH, to improve take rate and growth of implanted cells for xenograft and tumorgraft models.
Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma and that play an essential role in tissue organization by influencing cell adhesion, migration, proliferation, and differentiation. The major components of BME include laminin, collagen IV, entactin, and heparin sulfate proteoglycans.
Specifications
Gelling Assay - Cultrex BME, Type 3 gels in less than 30 minutes at 37 °C, and maintains the gelled form in culture medium for a minimum of 7 days at 37 °C.
Limitations
For research use only. Not for diagnostic use.
Product Datasheets
Citations for Cultrex Basement Membrane Extract, Type 3, Pathclear
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
17
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Glycosaminoglycan-mediated lipoprotein uptake protects cancer cells from ferroptosis
Authors: Calhoon, D;Sang, L;Bezwada, D;Kim, N;Basu, A;Hsu, SC;Pimentel, A;Brooks, B;La, K;Serrano, AP;Cassidy, DL;Cai, L;Toffessi-Tcheuyap, V;Margulis, V;Cai, F;Brugarolas, J;Weiss, RJ;DeBerardinis, RJ;Birsoy, K;Garcia-Bermudez, J;
bioRxiv : the preprint server for biology 2024-05-13
-
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
Authors: Soumoy, L;Genbauffe, A;Mouchart, L;Sperone, A;Trelcat, A;Mukeba-Harchies, L;Wells, M;Blankert, B;Najem, A;Ghanem, G;Saussez, S;Journe, F;
Cancer cell international 2024-01-04
-
Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma
Authors: Chougoni, KK;Park, H;Damle, PK;Mason, T;Cheng, B;Dcona, MM;Szomju, B;Dozmorov, MG;Idowu, MO;Grossman, SR;
Oncogenesis 2023-11-10
-
Combination of Polymeric Micelle Formulation of TGF beta Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC
Authors: Vinod, N;Hwang, D;Fussell, SC;Owens, TC;Tofade, OC;Copling, S;Ramsey, JD;Rädler, PD;Atkins, HM;Livingston, EE;Ashley Ezzell, J;Papkov, MS;Yuan, H;Perou, CM;Kabanov, AV;
bioRxiv : the preprint server for biology 2023-06-14
-
Deficiency of the Polycomb protein RYBP and TET methylcytosine oxidases promotes extensive CpG island hypermethylation and malignant transformation
Authors: Cui, W;Huang, Z;Jin, SG;Johnson, J;Lau, KH;Hostetter, G;Pfeifer, GP;
Cancer research 2023-06-06
-
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer
Authors: Yi, Q;Liu, W;Seo, JH;Su, J;Alaoui-Jamali, MA;Luo, J;Lin, R;Wu, JH;
Molecular cancer therapeutics 2023-05-04
-
Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Authors: Delbart, W;Marin, G;Stamatopoulos, B;de Wind, R;Sirtaine, N;Demetter, P;Vercruyssen, M;Woff, E;Karfis, I;Ghanem, GE;Flamen, P;Wimana, Z;
Cancers 2023-04-17
-
SFyNCS detects oncogenic fusions involving non-coding sequences in cancer
Authors: X Zhong, J Luan, A Yu, A Lee-Hasset, Y Miao, L Yang
bioRxiv : the preprint server for biology, 2023-04-06;0(0):. 2023-04-06
-
Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review
Authors: M Londoño-Be, C Castro, A Cañas, I Ortiz, M Osorio
Pharmaceutics, 2022-12-03;14(12):. 2022-12-03
-
In vitro and in ovo impact of the ionic dissolution products of boron-doped bioactive silicate glasses on cell viability, osteogenesis and angiogenesis
Authors: S Decker, M Arango-Osp, F Rehder, A Moghaddam, R Simon, C Merle, T Renkawitz, AR Boccaccini, F Westhauser
Scientific Reports, 2022-05-20;12(1):8510. 2022-05-20
-
Three-Dimensional Kidney-on-a-Chip Assessment of Contrast-Induced Kidney Injury: Osmolality and Viscosity
Authors: K Kim, B Jeong, YM Lee, HE Son, JY Ryu, S Park, JC Jeong, HJ Chin, S Kim
Micromachines, 2022-04-28;13(5):. 2022-04-28
-
Early Warnings by Liver Organoids on Short- and Long-Chain PFAS Toxicity
Authors: S Palazzolo, I Caligiuri, AA Sfriso, M Mauceri, R Rotondo, D Campagnol, V Canzonieri, F Rizzolio
Toxics, 2022-02-18;10(2):. 2022-02-18
-
Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer
Authors: L Yin, Y Zeng, R Zeng, Y Chen, TL Wang, KJ Rodabaugh, F Yu, A Natarajan, AR Karpf, J Dong
Oncogene, 2021-11-19;0(0):. 2021-11-19
-
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
Authors: CM Yamazaki, A Yamaguchi, Y Anami, W Xiong, Y Otani, J Lee, NT Ueno, N Zhang, Z An, K Tsuchikama
Nature Communications, 2021-06-10;12(1):3528. 2021-06-10
-
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Authors: R Yang, L Sun, CF Li, YH Wang, J Yao, H Li, M Yan, WC Chang, JM Hsu, JH Cha, JL Hsu, CW Chou, X Sun, Y Deng, CK Chou, D Yu, MC Hung
Nature Communications, 2021-02-05;12(1):832. 2021-02-05
-
GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein
Authors: J Cheng, LR Klei, NE Hubel, M Zhang, R Schairer, LM Maurer, HB Klei, H Kang, VJ Concel, PC Delekta, EV Dang, MA Mintz, M Baens, JG Cyster, N Parameswar, M Thome, PC Lucas, LM McAllister
J. Clin. Invest., 2020-02-03;130(2):1036-1051. 2020-02-03
-
Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma.
Authors: Doci C, Mikelis C, Lionakis M, Molinolo A, Gutkind J
Cancer Res, 2015-05-07;75(14):2937-48. 2015-05-07
FAQs
No product specific FAQs exist for this product, however you may
View all FAQsReviews for Cultrex Basement Membrane Extract, Type 3, Pathclear
Average Rating: 5 (Based on 3 Reviews)
Have you used Cultrex Basement Membrane Extract, Type 3, Pathclear?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
